Amy Schulman
VCManaging Partner, Polaris Partners
Pharma executive turned early-stage biotech investor
Background
Amy Schulman joined Polaris Partners in 2014 and co-founded the Polaris Innovation Fund in 2017, which invests in early-stage academic biotech spinouts. Previously she served as General Counsel and President of nutrition and consumer healthcare divisions at Pfizer, and was a Partner at DLA Piper starting her legal career at Cleary Gottlieb. She is a Senior Lecturer at Harvard Business School, Chair of the Board of Alnylam Pharmaceuticals (NASDAQ: ALNY), and a board member of Elevance Health (NYSE: ELV). She holds degrees from Wesleyan University and Yale Law School.
Investment Thesis
Academic biotech spinouts and early-stage companies where novel science can be translated into transformative medicines and products.
Investment Focus
Stages
Sectors
Based in: Boston, MA (North America)